Cipla Ltd. v. F. Hoffmann-La Roche Ltd. & Another

High Court of Delhi at New Delhi | Decided: 24 August 2012 FAO (OS) No. 188 of 2009 & FAO (OS) No. 190 of 2009 Bench: Hon’ble Mr. Justice Sanjay Kishan Kaul & Hon’ble Mr. Justice Indermeet Kaur (Division Bench) Citation: 2012 SCC OnLine Del 3707 | (2012) 52 PTC 1 (Del) (DB)

Background

F. Hoffmann-La Roche Ltd., a Swiss pharmaceutical corporation and OSI Pharmaceuticals Inc., an American company, were the joint holders of Indian Patent No. 196774, granted in respect of the anti-cancer drug erlotinib hydrochloride, marketed internationally under the brand name Tarceva. Erlotinib is an epidermal growth factor receptor inhibitor used primarily in the treatment of non-small cell lung cancer and pancreatic cancer. The drug works by blocking the action of the epidermal growth factor receptor tyrosine kinase enzyme, thereby inhibiting the proliferation of cancerous cells. At the time of the litigation, Tarceva was priced at approximately Rs. 4,800 per tablet, making a monthly course of treatment cost in the region of Rs. 1,50,000, a sum entirely beyond the reach of the overwhelming majority of Indian cancer patients.

Cipla Limited, one of India’s largest and most prominent generic pharmaceutical manufacturers, announced in early 2008 that it intended to launch a generic version of erlotinib under the brand name Erlocip at a price significantly lower than that of Tarceva – reportedly at approximately one-third of the price charged by Roche. Cipla’s stated position was that the patent held by Roche and OSI was vulnerable to challenge and that it was prepared to face litigation rather than allow cancer patients to be denied access to an affordable version of a life-saving medicine. This announcement placed the dispute at the centre of a broader national and international debate about the tension between pharmaceutical patent rights and the right of patients in developing countries to access essential medicines at affordable prices.

Roche and OSI filed a suit for infringement of their patent before the Delhi High Court, being CS (OS) No. 89 of 2008 and simultaneously sought an ex parte ad-interim injunction restraining Cipla from manufacturing and selling Erlocip. The Single Judge, R.S. Endlaw J., by his order dated 19 March 2008, declined to grant the ex parte injunction, noting that Cipla had raised a credible challenge to the validity of the patent and that the balance of convenience, particularly having regard to the public interest in access to affordable cancer medication, did not favour the grant of an injunction at that stage. Roche and OSI appealed against this refusal to the Division Bench in FAO (OS) No. 188 of 2009, while Cipla filed a cross appeal in FAO (OS) No. 190 of 2009 raising certain additional contentions. Both appeals were heard together and decided by the Division Bench by the present judgment.

The patent in question, No. 196774, covered erlotinib in its polymorph A form – the specific crystalline form used in Tarceva. Cipla contended that the patent was vulnerable to revocation on multiple grounds including lack of novelty, absence of inventive step and failure to satisfy the requirements of Section 3(d) of the Patents Act, 1970. Cipla also contended that the patent as granted covered polymorph A specifically and that Erlocip used a different polymorph – polymorph B – which was not covered by the claims of the patent. Roche disputed this and maintained that the patent covered erlotinib in all its forms and that Cipla’s product infringed the patent regardless of which polymorph it used. The technical dispute about the polymorph used in Cipla’s product and the scope of the patent claims with respect to polymorphs, were central questions in both the infringement and validity analysis.

The matter also raised profound questions of public interest and access to medicines that the court was called upon to weigh in the context of the balance of convenience analysis. Roche maintained that an injunction was essential to protect its patent rights and to preserve incentives for pharmaceutical innovation. Cipla argued that the grant of an injunction would effectively remove an affordable cancer drug from the Indian market and condemn thousands of patients who could not afford Tarceva to being deprived of treatment. Various civil society organisations and patient advocacy groups took a keen interest in the proceedings, underscoring the significance of the case far beyond its immediate commercial dimensions.

Issues for Determination

Whether the Single Judge was correct in refusing to grant an ad-interim injunction restraining Cipla from manufacturing, selling and distributing Erlocip pending the final disposal of the infringement suit.
Whether Roche and OSI established a prima facie case of infringement of Indian Patent No. 196774 at the interlocutory stage, having regard to the scope of the patent claims and the nature of Cipla’s product.
Whether Cipla raised a credible and prima facie tenable challenge to the validity of Patent No. 196774, including on grounds of lack of novelty, absence of inventive step and non-compliance with Section 3(d) of the Patents Act, 1970.
Whether the technical dispute regarding which polymorph of erlotinib was used in Cipla’s Erlocip product — polymorph A as covered by the Roche patent or polymorph B which may fall outside its claims — was a triable issue that militated against the grant of an interim injunction.
Whether public interest in access to affordable medicines for life-threatening conditions constitutes a relevant and legally cognisable factor in the balance of convenience analysis at the interlocutory stage in patent infringement suits involving pharmaceutical products.
Whether damages would constitute an adequate remedy for Roche in the event that the injunction was refused and Cipla was ultimately found to have infringed and conversely whether Cipla could be adequately compensated under a cross-undertaking in damages if the injunction was granted and Roche ultimately failed.

Key Holdings of the Court

First, the Division Bench upheld the Single Judge’s refusal to grant an ad-interim injunction and dismissed Roche’s appeal, affirming that this was not a case where the plaintiff’s right to an interim injunction was clear or free from doubt.

Second, the court held that Cipla had raised a prima facie credible challenge to the validity of Patent No. 196774. The court found that the challenges to novelty, inventive step and compliance with Section 3(d) of the Patents Act were not frivolous and raised genuine triable issues that could only be resolved at trial after full evidence and expert testimony.

Third, the court held that the dispute regarding which polymorph of erlotinib was used in Cipla’s product was a genuine triable question of fact. If Cipla’s Erlocip used polymorph B rather than polymorph A covered by the patent, the question of infringement itself would not be established and this uncertainty militated strongly against the grant of an interim injunction.

Fourth, the court made a significant pronouncement on the relevance of public interest in the balance of convenience analysis. It held that in cases involving life-saving pharmaceutical products and patents, the court is entitled — and indeed required — to weigh public interest in access to affordable medicines as a factor in the balance of convenience. The court observed that refusing an injunction in the circumstances of the present case was consistent with India’s obligations under the TRIPS Agreement and with the legislative policy reflected in the provisions of the Patents Act, 1970 as amended.

Fifth, the court held that Roche’s remedy in the event of ultimate success at trial lay in damages rather than injunction and that the financial resources of Cipla were sufficient to meet any damages award. The court noted that Roche had not demonstrated that damages would be an inadequate remedy in its specific circumstances.

Sixth, both appeals were accordingly dismissed and the suit was directed to proceed to trial expeditiously. The court also made observations about the need for Indian courts to develop a more nuanced approach to patent injunctions in the pharmaceutical sector, taking into account the specific public interest dimensions of such cases.

Statutory Provisions Involved

Section 48 of the Patents Act, 1970 confers upon a patentee the exclusive right to prevent third parties from making, using, offering for sale, selling or importing the patented product in India without consent. This provision formed the basis of Roche’s claim for injunctive relief, as it establishes the statutory foundation of a patentee’s right to exclude others from the commercial exploitation of the patented invention during the patent term.

Section 3(d) of the Patents Act, 1970, as amended by the Patents (Amendment) Act, 2005, provides that the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance shall not constitute a patentable invention. Cipla relied on this provision to challenge the validity of the Roche patent, contending that the specific polymorph A form of erlotinib covered by the patent did not demonstrate significantly enhanced efficacy over the known compound erlotinib and was therefore not patentable. This provision was at the heart of the validity challenge and was considered by the court in the context of the prima facie triability assessment.

Section 64 of the Patents Act, 1970 sets out the grounds on which a patent may be revoked, including lack of novelty, absence of inventive step and non-compliance with the requirements of patentability. Cipla’s challenge to the validity of the Roche patent at the interlocutory stage was framed with reference to these grounds and the court assessed whether the challenge raised triable issues under each ground.

Section 107 of the Patents Act, 1970 provides that every ground on which a patent may be revoked under Section 64 shall be available as a defence in any proceedings for infringement of the patent. This provision enabled Cipla to raise the invalidity of the patent as a defence in the infringement suit rather than being confined to separate revocation proceedings.

Order XXXIX Rules 1 and 2 of the Civil Procedure Code, 1908 govern the grant of temporary injunctions and require the applicant to establish a prima facie case, demonstrate that the balance of convenience lies in its favour and show that refusal of the injunction would cause irreparable harm. The court applied this tripartite framework to determine whether the interim injunction sought by Roche ought to be granted.

Article 27 of the TRIPS Agreement requires WTO Member States to make patents available for any inventions in all fields of technology without discrimination. The court referred to the TRIPS Agreement and the Doha Declaration on TRIPS and Public Health in the context of its analysis of the public interest dimension of the balance of convenience, noting that the Indian Patents Act as amended reflects India’s exercise of the flexibilities available under TRIPS to balance patent rights with public health objectives.

Reasoning of the Court

The Division Bench approached the question of interim injunction through the classical tripartite framework of prima facie case, balance of convenience and irreparable harm, but applied each limb of the test with a degree of nuance and contextual sensitivity that makes this judgment particularly significant. The court was careful to emphasise that at the interlocutory stage it was not called upon to decide the questions of infringement or validity finally — its function was to assess whether genuine triable issues existed and where the balance of justice lay pending trial.

On the question of prima facie case, the court found that while Roche had demonstrated a prima facie case of infringement based on the patent claims and the similarity of Cipla’s product, this case was not so clear and overwhelming as to override the other considerations. The critical complication was the polymorph dispute. Cipla had maintained throughout that its Erlocip product used polymorph B of erlotinib, which was not covered by Patent No. 196774. Roche disputed this and contended that testing of the product showed the presence of polymorph A. The court found that this technical dispute about the composition of Cipla’s product could not be resolved on affidavit evidence alone and required a full trial with expert testimony. This uncertainty in the infringement analysis significantly weakened the case for granting an injunction, since an injunction premised on infringement of a patent that may not even be infringed would cause unjustified harm to Cipla and to the patients relying on its product.

On the validity challenge, the court found that Cipla had placed before it a credible and substantiated challenge to the patent, including specific arguments on lack of novelty, obviousness and Section 3(d). The court noted that the questions raised by Cipla were serious and could not be dismissed summarily. In particular, the challenge under Section 3(d) raised a question of whether the specific polymorph A form demonstrated significantly enhanced therapeutic efficacy over erlotinib as previously known — a question that the Supreme Court would later address definitively in the Novartis case decided in 2013. The presence of a serious and substantiated validity challenge reinforced the court’s conclusion that the case was not appropriate for the grant of an interim injunction.

On the balance of convenience and public interest, the court made observations of lasting significance. It held that in pharmaceutical patent cases involving life-saving medicines, the court cannot shut its eyes to the impact that granting or refusing an injunction would have on patients who depend on access to affordable treatment. The court noted that Tarceva was priced at a level that made it inaccessible to the vast majority of Indian cancer patients, while Erlocip was available at a fraction of that price. Withdrawing Erlocip from the market by granting an injunction would effectively remove an affordable treatment option for patients who had no alternative. The court held that this consideration of public interest in access to medicines was a legitimate and weighty factor in the balance of convenience analysis and that it tipped the balance decisively against the grant of an injunction.

The court also addressed the adequacy of damages as a remedy. It found that if Roche ultimately succeeded at trial and proved infringement, it could be adequately compensated by an award of damages, given Cipla’s substantial financial resources and the fact that Cipla was marketing Erlocip openly and with full knowledge of the Roche patent. A situation of concealment or dissipation of assets that might have rendered a damages award ineffective was not present. Conversely, if an injunction were granted and Roche ultimately failed at trial, the harm to Cipla in terms of lost market and the harm to patients in terms of lost access to an affordable medicine would be difficult to quantify and compensate adequately under a cross-undertaking in damages.

Doctrinal Significance

The Cipla v. Roche judgment is one of the most consequential decisions in the history of Indian patent law, establishing for the first time in a Division Bench judgment of the Delhi High Court that public interest in access to affordable medicines is a legally cognisable and substantively weighty factor in the balance of convenience analysis in pharmaceutical patent infringement suits. Prior to this decision, Indian courts had tended to apply the classical tripartite test for interlocutory injunctions without explicit reference to public interest as an independent consideration. By holding that the impact on patients and the broader public health consequences of granting or withholding an injunction must be factored into the balance of convenience, the court fundamentally expanded the analytical framework for pharmaceutical patent injunctions in India.

The judgment also makes an important contribution to the doctrine of prima facie case in patent infringement proceedings by holding that a genuine dispute about the scope of the patent claims — in this case the polymorph dispute — can by itself militate against the grant of an interim injunction even where the patentee has a facially strong case. This reflects a mature and technically sensitive approach to patent interlocutory hearings, recognising that the grant of an interim injunction based on a disputed and technically complex claim construction question could cause serious and irreversible harm if the construction ultimately adopted at trial differs from that assumed at the interlocutory stage.

The case is also significant for its treatment of the relationship between TRIPS obligations and domestic patent law in the context of access to medicines. By explicitly referring to the Doha Declaration on TRIPS and Public Health and to India’s use of TRIPS flexibilities in the Patents Act, 1970, the court aligned its decision with the international consensus that patent rights in the pharmaceutical sector must be balanced against the imperative of protecting public health. This aspect of the judgment has been widely cited in academic literature and international policy discussions as an example of a developing country court giving practical effect to the access to medicines flexibilities contemplated by the TRIPS framework.

The judgment’s treatment of Section 3(d) as a triable issue of validity, while not resolving the question definitively, contributed to the doctrinal development that culminated in the Supreme Court’s landmark ruling in Novartis AG v. Union of India in 2013. By treating the Section 3(d) challenge as substantive and credible rather than dismissing it summarily at the interlocutory stage, the Division Bench signalled that the provision had genuine teeth as a barrier to the patenting of incremental pharmaceutical modifications and that courts would take such challenges seriously even at the interim stage. This approach helped shape the trajectory of Section 3(d) jurisprudence in the years leading up to the Novartis decision.

Finally, the judgment has had a lasting influence on patent litigation practice and strategy in India. It established that pharmaceutical patent holders face a higher practical threshold for obtaining interim injunctions than patentees in other fields, because the public interest dimension and the access to medicines considerations carry significant weight in the balance of convenience analysis. This has influenced the way pharmaceutical patent disputes are framed and argued before Indian courts, with defendants in such cases routinely raising public interest arguments and patentees being required to address the access implications of injunctive relief. The judgment thus represents a defining moment in the evolution of Indian patent jurisprudence at the intersection of intellectual property rights and public health policy.